{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T12:12:10Z","timestamp":1785845530868,"version":"3.56.0"},"reference-count":29,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"CDC"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Influenza A(H7N9) viruses remain as a high pandemic threat. The continued evolution of the A(H7N9) viruses poses major challenges in pandemic preparedness strategies through vaccination. We assessed the breadth of the heterologous neutralizing antibody responses against the 3rd and 5th wave A(H7N9) viruses using the 1st wave vaccine sera from 4 vaccine groups: 1. inactivated vaccine with 2.8 \u03bcg hemagglutinin (HA)\/dose + AS03A; 2. inactivated vaccine with 5.75 \u03bcg HA\/dose + AS03A; 3. inactivated vaccine with 11.5 \u03bcg HA\/dose + MF59; and 4. recombinant virus like particle (VLP) vaccine with 15 \u03bcg HA\/dose + ISCOMATRIX\u2122. Vaccine group 1 had the highest antibody responses to the vaccine virus and the 3rd\/5th wave drifted viruses. Notably, the relative levels of cross-reactivity to the drifted viruses as measured by the antibody GMT ratios to the 5th wave viruses were similar across all 4 vaccine groups. The 1st wave vaccines induced robust responses to the 3rd and Pearl River Delta lineage 5th wave viruses but lower cross-reactivity to the highly pathogenic 5th wave A(H7N9) virus. The population in the United States was largely immunologically naive to the A(H7N9) HA. Seasonal vaccination induced cross-reactive neuraminidase inhibition and binding antibodies to N9, but minimal cross-reactive antibody-dependent cell-mediated cytotoxicity (ADCC) antibodies to A(H7N9).<\/jats:p>","DOI":"10.3390\/vaccines10111856","type":"journal-article","created":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T03:44:17Z","timestamp":1667360657000},"page":"1856","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Influenza A(H7N9) Pandemic Preparedness: Assessment of the Breadth of Heterologous Antibody Responses to Emerging Viruses from Multiple Pre-Pandemic Vaccines and Population Immunity"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3197-1649","authenticated-orcid":false,"given":"Min Z.","family":"Levine","sequence":"first","affiliation":[{"name":"Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30329, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Crystal","family":"Holiday","sequence":"additional","affiliation":[{"name":"Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30329, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaohui","family":"Bai","sequence":"additional","affiliation":[{"name":"Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30329, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weimin","family":"Zhong","sequence":"additional","affiliation":[{"name":"Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30329, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Liu","sequence":"additional","affiliation":[{"name":"Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30329, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacie","family":"Jefferson","sequence":"additional","affiliation":[{"name":"Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30329, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F. Liaini","family":"Gross","sequence":"additional","affiliation":[{"name":"Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30329, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-pin","family":"Tzeng","sequence":"additional","affiliation":[{"name":"Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30329, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis","family":"Fries","sequence":"additional","affiliation":[{"name":"Novavax, Inc., Gaithersburg, MD 20878, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gale","family":"Smith","sequence":"additional","affiliation":[{"name":"Novavax, Inc., Gaithersburg, MD 20878, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Boutet","sequence":"additional","affiliation":[{"name":"GSK, 1300 Wavre, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damien","family":"Friel","sequence":"additional","affiliation":[{"name":"GSK, 1300 Wavre, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1753-7248","authenticated-orcid":false,"given":"Bruce L.","family":"Innis","sequence":"additional","affiliation":[{"name":"GSK, Rockville, MD 20850, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6232-8111","authenticated-orcid":false,"given":"Corey P.","family":"Mallett","sequence":"additional","affiliation":[{"name":"GSK, Rockville, MD 20850, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Todd","family":"Davis","sequence":"additional","affiliation":[{"name":"Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30329, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5190-980X","authenticated-orcid":false,"given":"David E.","family":"Wentworth","sequence":"additional","affiliation":[{"name":"Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30329, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian A.","family":"York","sequence":"additional","affiliation":[{"name":"Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30329, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2352-3886","authenticated-orcid":false,"given":"James","family":"Stevens","sequence":"additional","affiliation":[{"name":"Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30329, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline M.","family":"Katz","sequence":"additional","affiliation":[{"name":"Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30329, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terrence","family":"Tumpey","sequence":"additional","affiliation":[{"name":"Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30329, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,11,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.3201\/eid2512.190261","article-title":"Avian Influenza A Viruses among Occupationally Exposed Populations, China, 2014\u20132016","volume":"25","author":"Quan","year":"2019","journal-title":"Emerg. Infect. Dis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3201\/eid2201.151330","article-title":"Avian Influenza A(H7N9) Virus Infection in 2 Travelers Returning from China to Canada, January 2015","volume":"22","author":"Skowronski","year":"2016","journal-title":"Emerg. Infect. Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e00301-18","DOI":"10.1128\/JVI.00301-18","article-title":"New Threats from H7N9 Influenza Virus: Spread and Evolution of High- and Low-Pathogenicity Variants with High Genomic Diversity in Wave Five","volume":"92","author":"Quan","year":"2018","journal-title":"J. Virol."},{"key":"ref_4","unstructured":"Food and Angriculture Organization (FAO) (2022, May 03). H7N9 Situation Update. Available online: https:\/\/www.fao.org\/ag\/againfo\/programmes\/en\/empres\/H7N9\/situation_update.html."},{"key":"ref_5","unstructured":"World Health Organization (WHO) (2022, May 03). Influenza at the human-Animal Interface. Available online: https:\/\/cdn.who.int\/media\/docs\/default-source\/influenza\/human-animal-interface-risk-assessments\/influenza_summary_ira_ha_interface_jan_2022.pdf?sfvrsn=1893dd9f_5&download=true."},{"key":"ref_6","unstructured":"CDC (2022, May 13). Summary of Influenza Risk Assessment Tool (IRAT) Results, Available online: https:\/\/www.cdc.gov\/flu\/pandemic-resources\/monitoring\/irat-virus-summaries.htm?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fflu%2Fpandemic-resources%2Ftools%2Firat-virus-summaries.htm#H7N9hongkong."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1093\/infdis\/jit430","article-title":"Avian-origin influenza A(H7N9) infection in influenza A(H7N9)-affected areas of China: A serological study","volume":"209","author":"Yang","year":"2014","journal-title":"J. Infect. Dis."},{"key":"ref_8","unstructured":"WHO (2022, May 13). Antigenic and Genetic Characteristics of Zoonotic Influenza Viruses and Development of Candidate Vaccine Viruses for Pandemic Preparedness. Available online: https:\/\/cdn.who.int\/media\/docs\/default-source\/influenza\/who-influenza-recommendations\/vcm-northern-hemisphere-recommendation-2017-2018\/201703_zoonotic_vaccinevirusupdate.pdf?sfvrsn=4c4920df_14."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1001\/jama.2015.7916","article-title":"Effect of Varying Doses of a Monovalent H7N9 Influenza Vaccine With and Without AS03 and MF59 Adjuvants on Immune Response: A Randomized Clinical Trial","volume":"314","author":"Jackson","year":"2015","journal-title":"JAMA"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1001\/jama.2014.12854","article-title":"Serological responses to an avian influenza A\/H7N9 vaccine mixed at the point-of-use with MF59 adjuvant: A randomized clinical trial","volume":"312","author":"Mulligan","year":"2014","journal-title":"JAMA"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41541-021-00287-7","article-title":"Adjuvanted recombinant hemagglutinin H7 vaccine to highly pathogenic influenza A(H7N9) elicits high and sustained antibody responses in healthy adults","volume":"6","author":"Oshansky","year":"2021","journal-title":"NPJ Vaccines"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3326","DOI":"10.1016\/j.vaccine.2019.04.074","article-title":"mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials","volume":"37","author":"Feldman","year":"2019","journal-title":"Vaccine"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.1056\/NEJMc1313186","article-title":"A recombinant viruslike particle influenza A (H7N9) vaccine","volume":"369","author":"Fries","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1093\/infdis\/jiw414","article-title":"Immunogenicity and Safety of an AS03-Adjuvanted H7N9 Pandemic Influenza Vaccine in a Randomized Trial in Healthy Adults","volume":"214","author":"Madan","year":"2016","journal-title":"J. Infect. Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"4305","DOI":"10.1016\/j.vaccine.2013.07.043","article-title":"Development of influenza H7N9 virus like particle (VLP) vaccine: Homologous A\/Anhui\/1\/2013 (H7N9) protection and heterologous A\/chicken\/Jalisco\/CPA1\/2012 (H7N3) cross-protection in vaccinated mice challenged with H7N9 virus","volume":"31","author":"Smith","year":"2013","journal-title":"Vaccine"},{"key":"ref_16","unstructured":"Network, W.G.I.S. (2022, May 13). Manual for the Labratory Diagnosis and Virological Surveillence of Influenza. Available online: http:\/\/whqlibdoc.who.int\/publications\/2011\/9789241548090_eng.pdf."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"S555","DOI":"10.1093\/infdis\/jix001","article-title":"Cross-Reactive Antibody Responses to Novel H5Nx Influenza Viruses Following Homologous and Heterologous Prime-Boost Vaccination with a Prepandemic Stockpiled A(H5N1) Vaccine in Humans","volume":"216","author":"Levine","year":"2017","journal-title":"J. Infect. Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jviromet.2014.09.003","article-title":"An optimized enzyme-linked lectin assay to measure influenza A virus neuraminidase inhibition antibody titers in human sera","volume":"210C","author":"Couzens","year":"2014","journal-title":"J. Virol. Methods"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"ofw102","DOI":"10.1093\/ofid\/ofw102","article-title":"Antibody-Dependent Cell-Mediated Cytotoxicity to Hemagglutinin of Influenza A Viruses After Influenza Vaccination in Humans","volume":"3","author":"Zhong","year":"2016","journal-title":"Open Forum Infect. Dis."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1093\/infdis\/jiz295","article-title":"Stockpiled Avian Influenza A(H7N9) Vaccines Induce Robust, Nonneutralizing Functional Antibodies Against Antigenically Drifted Fifth-Wave A(H7N9) Viruses","volume":"220","author":"Zhong","year":"2019","journal-title":"J. Infect. Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1093\/infdis\/jiu186","article-title":"Association between antibody titers and protection against influenza virus infection within households","volume":"210","author":"Tsang","year":"2014","journal-title":"J. Infect. Dis."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41541-019-0114-8","article-title":"Heterologous prime-boost with A(H5N1) pandemic influenza vaccines induces broader cross-clade antibody responses than homologous prime-boost","volume":"4","author":"Levine","year":"2019","journal-title":"NPJ Vaccines"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1056\/NEJMoa2110362","article-title":"Effectiveness of Covid-19 Vaccines in Ambulatory and Inpatient Care Settings","volume":"385","author":"Thompson","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1586\/erv.13.35","article-title":"Immunological assessment of influenza vaccines and immune correlates of protection","volume":"12","author":"Reber","year":"2013","journal-title":"Expert Rev. Vaccines"},{"key":"ref_25","first-page":"767","article-title":"The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses","volume":"70","author":"Hobson","year":"1972","journal-title":"J. Hyg."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"ofv067","DOI":"10.1093\/ofid\/ofv067","article-title":"Hemagglutination Inhibition Antibody Titers as a Correlate of Protection Against Seasonal A\/H3N2 Influenza Disease","volume":"2","author":"Benoit","year":"2015","journal-title":"Open Forum Infect. Dis."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.jinf.2014.09.003","article-title":"Hemagglutination inhibiting antibodies and protection against seasonal and pandemic influenza infection","volume":"70","author":"Fox","year":"2015","journal-title":"J. Infect."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Rajendran, M., Krammer, F., and McMahon, M. (2021). The Human Antibody Response to the Influenza Virus Neuraminidase Following Infection or Vaccination. Vaccines, 9.","DOI":"10.3390\/vaccines9080846"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1093\/infdis\/jiv195","article-title":"Antibody to Influenza Virus Neuraminidase: An Independent Correlate of Protection","volume":"212","author":"Monto","year":"2015","journal-title":"J. Infect. Dis."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/10\/11\/1856\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:08:56Z","timestamp":1760144936000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/10\/11\/1856"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,1]]},"references-count":29,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,11]]}},"alternative-id":["vaccines10111856"],"URL":"https:\/\/doi.org\/10.3390\/vaccines10111856","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,1]]}}}